J8502 Aprepitant Injection HCPCS Reimbursement

HCPCS Level II code J8502 designates a 1 mg injectable unit of aprepitant (brand name Aponvie), an NK1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting. This code matters nationally as it standardizes billing for a high-cost, specialty antiemetic administered in outpatient infusion and clinic settings, affecting oncology supportive care workflows and drug cost management.

Key payers in the scope of analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use in chemotherapy supportive care. The publication summarizes reimbursement benchmarks and coding relationships where available, highlights payer coverage trends and policy considerations relevant to specialty injectable antiemetics, and outlines operational implications for billing and documentation.

The content is aimed at billing managers, oncology pharmacists, practice administrators, and policy analysts seeking a compact reference to HCPCS Level II code J8502, its clinical role, and how payers commonly approach coverage and payment for injectable aprepitant.

Billing Code Overview

HCPCS Level II code J8502 represents an injection of aprepitant (Aponvie), 1 mg. This code is used to bill for the drug product delivered via injection form and reflects the per-milligram unit of aprepitant supplied for intravenous administration.

Service type: injectable antiemetic / neurokinin-1 (NK1) receptor antagonist

Typical site of service: infusion center, hospital outpatient department, or clinic setting

Data not available in the input.

Clinical Context

A typical patient is an adult oncology patient receiving highly emetogenic chemotherapy for which neurokinin-1 receptor antagonist therapy is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). In an outpatient oncology infusion center or hospital outpatient department, a clinician orders J8502 (injection, aprepitant (aponvie), 1 mg) to be administered intravenously or orally per the product formulation and institutional protocol. The clinical workflow includes medication reconciliation, verification of chemotherapy regimen and CINV risk, order entry into the electronic health record, pharmacist preparation/dosing verification, administration by an infusion nurse, documentation of lot number and dose in the medication administration record, and monitoring for adverse reactions. Typical sites of service include an infusion center, hospital outpatient department, or oncology clinic where supportive antiemetic therapy is provided as part of a chemotherapy visit. Patient education addresses expected effects, timing relative to chemotherapy, and instructions for additional oral dosing when applicable.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure	Use when a distinct E/M visit is performed the same day as administration for issues beyond routine medication administration.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Medical Oncology	Primary specialty prescribing and overseeing antiemetic regimens for chemotherapy patients.
`207RC0000X`	Radiation Oncology	May prescribe antiemetics for patients receiving concurrent chemoradiation with emetogenic potential.
`208000000X`	Internal Medicine	Hospitalists or internists managing inpatient chemotherapy or supportive care.
`2930C0001X`	Clinical Pharmacist	Pharmacists preparing and verifying dosing, especially for specialty injectable agents.
`364S00000X`	Registered Nurse	Nurses administer IV medications and document administration in infusion settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z51.11`	Encounter for antineoplastic chemotherapy	Common primary diagnosis code for visits where antiemetic `J8502` is administered as part of chemotherapy supportive care.
`Z92.21`	Personal history of antineoplastic chemotherapy	Used for follow-up care related to history of chemotherapy when antiemetic therapy may be given around recurrence or additional treatment.
`C80.1`	Malignant (primary) neoplasm, unspecified site, with metastasis	Represents oncology patients receiving systemic therapy who may require prophylactic antiemetics.
`C50.9`	Malignant neoplasm of breast, unspecified	Example cancer diagnosis frequently treated with emetogenic regimens requiring NK1 receptor antagonists.
`C61`	Malignant neoplasm of prostate	Another common malignancy where systemic therapy and supportive antiemetic care are provided.
`R11.0`	Nausea with vomiting	Symptom code used when documenting treatment for active nausea/vomiting in conjunction with antiemetic administration.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Often billed for the IV administration visit when `J8502` is given as part of an infusion encounter.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Billed when infusion monitoring extends beyond the initial hour during the same visit.
`96413`	Chemotherapy administration, intravenous infusion technique; infusion, up to 1 hour, single or initial substance/drug	Billed when chemotherapy agents are administered; antiemetic `J8502` is administered in the same visit as chemotherapy.
`96415`	Chemotherapy administration, each additional hour	Used when chemotherapy infusion continues beyond the initial hour and is part of the same session as antiemetic administration.
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Billed when `J8502` (if given via non-IV injectable route in applicable formulation) is administered as an injection separate from an infusion.
`90899`	Unlisted procedure, psychiatry and neurology (placeholder example)	Data not typically applicable; included only when an unusual or unlisted service accompanies antiemetic therapy.

OpenPayer

Summary & Overview

HCPCS J8502: Injection of aprepitant (Aponvie), 1 mg